About WinSanTor
WinSanTor is a company based in San Diego (United States) founded in 2011 by Nigel Calcutt, Paul Fernyhough, and Stanley Kim. WinSanTor has raised $782.94 thousand across 1 funding round. WinSanTor offers products and services including WST-057 and Clinical Trials Program. WinSanTor operates in a competitive market with competitors including Avidity Biosciences, Flexion Therapeutics, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
- Total Equity Funding$782.94K (USD)
in 1 rounds
- Latest Funding Round$782.94K (USD), Seed
Nov 2017
Products & Services of WinSanTor
WinSanTor offers a comprehensive portfolio of products and services, including WST-057 and Clinical Trials Program.
Lead drug for treating diabetic peripheral neuropathy in trials
Platform for enrolling patients in neuropathy research studies
Apps and channels of WinSanTor
its YouTube channel WinSanTor has 1.85K subscribers and 30 videos.
Videos from WinSanTor
The most watched videos on WinSanTor's YouTube channel, WinSanTor (1.85K subscribers). Click a video to play it here.
More on WinSanTor.
Funding Insights of WinSanTor
WinSanTor has successfully raised a total of $782.94K through 1 strategic funding round. The most recent funding activity was a Seed round of $782.94 thousand completed in November 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $782,939
- Total Rounds 1
- Last Round Seed — $782,939
- First Round $782,939
(Nov 2017)
All 1 funding rounds of WinSanTor with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2017 | $782,939 | Seed | – | – | – |
People of WinSanTor
5 people are tracked at WinSanTor (4 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Nigel Calcutt | Co-Founder | Leadership |
Paul Fernyhough | Co-Founder | Leadership |
Stanley Kim | Co-Founder & CEO | Leadership |
Andrew Albertson | Chief Financial Officer | Leadership |
Christian Alexander Ihm | Business Development Manager | Team |
Complete people profiles for WinSanTor
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of WinSanTor
2 dated milestones of WinSanTor across 6 years, from founding to its latest funding, stage changes and deals.
- Founded WinSanTor is founded.
- Funding First funding round of $783K.
Competitors of WinSanTor
WinSanTor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Flexion Therapeutics, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. |
Detailed competitors of WinSanTor
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of WinSanTor
The website of WinSanTor (winsantor.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▼ 41.8% vs previous month
Websites whose visitors overlap most with WinSanTor. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| diazyme.com | 100% | 5.2K | #3,824,160 | View details | |
s4me.info | s4me.info | 94% | – | #223,111 | – |
| tandemdiabetes.com | 80% | 384.6K | #102,653 | View details | |
| dexcom.com | 80% | 2.8M | #19,957 | View details | |
| ctkbiotech.com | 74% | 15.8K | #1,803,743 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for WinSanTor
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to WinSanTor
10 companies that operate in the same segment as WinSanTor (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about WinSanTor
WinSanTor was founded in 2011 and raised its 1st funding round 6 years after it was founded.
WinSanTor is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Stanley Kim is the current CEO of WinSanTor. They have also founded this company.
WinSanTor is a funded company, having raised a total of $782.94K across 1 funding round to date. The company's 1st funding round was a Seed of $782.94K, raised on Nov 2017.
WinSanTor is an early clinical stage drug discovery company that is developing a small molecule treatment for neuropathies, with a focus on diabetic peripheral neuropathy. The company is targeting a novel pathway that acts to constrain the growth capacity and plasticity of axon terminals in normal individuals. By inhibiting this system using selective antagonists, it is possible to enhance growth and plasticity of neurons, thereby offering a way to reverse nerve damage observed in early diabetic neuropathy. WinSanTor has a lead candidate in early clinical trials called Pirenzepine (possibly, WST01) which in multiple pre-clinical in vivo tests has been shown to prevent as well as reverse the symptoms of early diabetic peripheral neuropathy including the ability to ameliorate both epidermal fiber loss and thermal hypoalgesia. The company has received 370,000 in Phase I SBIR grant from NIH for fast track development of the candidate molecule.
WinSanTor's top competitors include Sutro Biopharma, Flexion Therapeutics and Avidity Biosciences.
WinSanTor offers WST-057 and Clinical Trials Program.
WinSanTor operates through Winsantor Inc.